SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending following news of a memorandum of understanding with the U.S. Department of Energy, sparking excitement about quantum technologies in space. Community discussions revolve around the company's growth potential, comparisons to other tech stocks, and debate over valuation amid a short squeeze. Some are closely watching for a potential Trump-related announcement that could further boost the stock.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as part of a broader surge in quantum computing stocks, with community members actively discussing its potential for significant gains. Optimism stems from upcoming events, potential government contracts, and the company's technology for optimization, though some express concerns about the current valuation. Overall, there's a sense of FOMO (fear of missing out) driving interest in QBTS.

BGM Group Ltd. is a pharmaceutical and chemical company. It focuses on the research, development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Licorice products include Gan Di Xin, Qilian Shan Licorice Extract, and Qilian Shan Licorice Liquid Extract. The Oxytetracycline products consists of Qilian Shan Oxytetracycline Tablets and Qilian Shan Oxytetracycline Active Pharmaceutical Ingredients (API). The TCMD product includes Ahan antibacterial paste, which is made from a mixture of traditional Chinese herbal ingredients. The heparin product includes Heparin Sodium Preparations. The Sausage Casings products include Zhu Xiaochang Sausage Casings, which are all-natural food products used for culinary purposes. The Fertilizer products is composed of Xiongguan Organic Fertilizer and Xiongguan Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.

BGM Group Ltd. - Ordinary Shares - Class A

BGM Group Ltd

BGM Group (BGM) is trending due to strong community interest in its AI pivot and recent earnings report, which highlighted revenue growth driven by AI and insurance businesses. Community members are closely watching key technical levels and institutional accumulation, speculating on potential catalysts for a breakout. The stock's unique combination of AI, fintech, and robotics is generating discussion about its long-term potential and comparison to other high-growth AI companies.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo ($MLGO) is trending as traders discuss its potential for a short squeeze and its connection to WIMI. The stock's small float and updates around AI and blockchain are attracting attention, with some highlighting its history of volatile runs and comparing it to other high-flying stocks. Community members are also weighing in on the company's fundamentals and potential catalysts, like a move into crypto.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending amid mixed sentiment, with some traders pointing to technical analysis suggesting a pullback before a potential move higher, while others cite regulatory scrutiny and cost pressures as reasons for concern. Discussions revolve around potential price targets, options activity, and speculation about upcoming news or a meeting with the Trump administration. Some investors view UNH as undervalued, while others anticipate a further decline.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market digests recent rate cut news and anticipates potential impacts on inflation and economic growth. Community discussions revolve around market direction, with some highlighting bullish signals and others warning of a potential downturn. Rotation into value stocks and the influence of AI on the job market are also being actively discussed.

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

89bio Inc

89bio is trending following news of its acquisition by Roche, driving excitement and speculation about the future of the MASH space. The community is discussing the potential $20.50 per share value for shareholders and what this acquisition means for other companies in the sector, with some highlighting $ETNB's long downtrend before the buyout news. Community members are now looking for the next potential buyout target in the biotech space.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares

SOXS is trending as traders discuss its continued decline despite some semi stocks showing weakness, with community members expressing frustration over the ETF's tracking and potential manipulation. Some are hoping for a market correction or hawkish comments from the Fed to provide a catalyst for a reversal. Others are speculating about potential impacts from upcoming earnings and economic data.

Bullish engages in the management of a digital asset platform. It also offers market infrastructure and information services. The company was founded by Brendan Francis Blumer in 2020 and is headquartered in George Town, Cayman Islands.

Bullish

Bullish is trending following the announcement of securing a BitLicense from the New York State Department of Financial Services, seen by the community as a significant step for U.S. expansion. Community members are also discussing the firm's earnings report, which beat analyst estimates. Some traders are expressing optimism for potential upgrades and a continued rally, while others remain cautious, citing past performance and broader market conditions.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology ($GRRR) is trending due to a recently announced $1.4 billion contract to build AI-powered data centers in Southeast Asia. While some investors are excited about the potential revenue growth and see it as a game-changer, others are skeptical, questioning the legitimacy of the partner company, Freyr, and the details of the deal. The community is actively discussing the implications of the contract and waiting for further validation from the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 149.7% in Mineralys Therapeutics, Inc. (MLYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why

Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?

The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 154.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy

Mineralys Therapeutics Inc. (195% increase in followers)Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone.Its lead candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor designed for cardiorenal conditions.Last month, Mineralys reported positive topline results from its Phase 3 Launch-HTN and Phase 2 Advance-HTN trials evaluating lorundrostat for uncontrolled and resistant hypertension. Both studies met their primary efficacy endpoints with statistical significance.&nbsp;In February, Mineralys reported a smaller-than-expected quarterly loss and disclosed that cash, cash equivalents, and investments stood at $198.2 million as of Dec. 31, 2024, which it expects to support clinical studies and corporate operations through the first quarter of 2026.The stock has gained over 28% year-to-date, with short interest at 4.5%, according to Koyfin.Sana Biotechnology Inc. (177% increase in followers)Sana focuses on developing engineered cell therapies to repair or replace damaged or missing cells, as well as control and modify genes.This year, the company has attracted significant investor interest following a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes. In January, it demonstrated that its hypoimmune edits enabled islet cell transplants to survive without immunosuppression, a result that drew praise from analysts.Last month, Citizens JMP upgraded Sana's stock, citing the validation of its Hypoimmune platform in type 1 diabetes, upcoming SC291 data in autoimmune diseases expected in 2025, and a strong cash position of $152.5 million. The firm considers Sana undervalued.Jefferies notes that Sana has three assets in development across different disease areas and projects peak adjusted revenues of $2.8 billion.Sana's stock is up just over 3% year-to-date, with short interest at 17.7%, according to Koyfin.Aeon Biopharma Inc. (132% increase in followers)This is a clinical-stage biopharmaceutical company developing ABP-450, a botulinum toxin complex for treating neurological conditions. Evolus markets the same botulinum toxin complex cosmetically under the name Jeuveau.ABP-450 is already approved as a biosimilar in Mexico and India. Aeon holds exclusive development and distribution rights for therapeutic indications in the U.S., Canada, the EU, the U.K., and select international markets.The stock gained attention this year following a 1-for-72 reverse stock split in March to maintain NYSE American's minimum share price requirement.Last month, Aeon announced that CEO Marc Forth would step down on April 4 to pursue another opportunity, with Chairman Jost Fischer stepping in as interim CEO.Aeon's stock has plunged over 98% year-to-date, with short interest last at 1.7%, according to Koyfin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.

Equity

Mineralys Therapeutics Inc. (123% jump in watchers)The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data from its Phase 3 and Phase 2 trials for lorundrostat in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Both trials met their primary efficacy endpoints, showing statistically significant blood pressure reductions.&nbsp;The company also announced a $250 million underwritten public offering to fund lorundrostat’s development and pre-commercialization efforts.Mineralys stock is up over 15% year-to-date (YTD).Tenaya Therapeutics Inc. (11% jump in watchers)Tenaya saw increased attention after reporting stronger-than-expected fourth-quarter earnings and highlighting upcoming clinical data readouts for its gene therapy programs targeting cardiomyopathies.&nbsp;CEO Faraz Ali noted continued progress in the TN-201 MyPEAK-1 and TN-401 RIDGE-1 trials.&nbsp;Tenaya’s stock remains down over 53% YTD.SpringWorks Therapeutics Inc. (10% jump in watchers)SpringWorks gained traction amid ongoing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-sees-biggest-weekly-biotech-jump-in-stocktwits-following/cheUZARRbb2">speculation</a> about a potential buyout by Merck KGaA. While Merck confirmed advanced merger discussions in its annual report, it stopped short of announcing a deal, leaving traders searching for clues. The company’s withdrawal from a Barclays healthcare conference further fueled speculation.&nbsp;SpringWorks stock is up more than 40% YTD.COSCIENS Biopharma Inc. (9% jump in watchers)COSCIENS initiated a Phase 2a clinical efficacy trial for its avenanthramides product, which is being explored for its anti-inflammatory properties. The trial, dubbed the AvenActive study, will assess safety and efficacy in two dosage arms.&nbsp;COSCIENS stock has gained over 20% YTD.Metagenomi Inc. (7% jump in watchers)Metagenomi published new research in Nature Communications on its novel CAST gene editing system, which enables precise, programmable integration of large gene cargoes. The technology could have major implications for treating genetic diseases like cystic fibrosis and Duchenne Muscular Dystrophy.&nbsp;Metagenomi stock is down more than 46% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.  

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of...

MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. (Mineralys or the Company) (NASDAQ: MLYS). Investors...

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$37.29
Prev Close	$37.42
Open	$37.42
Dividend Yield	0.00%
50-Day Moving Average	$18.82
Beta	0.00
Avg. Volume	934,976.67
PE Ratio	-10.49

52-Week High	$39.20
52-Week Low	$8.24
Market Capitalization	$2.48B
EPS (Annual)	-$3.66
Price to Book	7.84
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MLYS
Mineralys Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MLYS News

MLYS Mineralys Therapeutics Inc